Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1

Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic later

Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide

OTS Rare Disease N-of-1+ Briefing Document, Jan 2020

Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease

Drug Regulation in the Era of Individualized Therapies